Category: Practice

GODDYN advised Celyad on agreement with Horizon Discovery

GODDYN has advised Celyad (Euronext Brussels and Paris, and NASDAQ: CYAD), a clinical-stage biopharmaceutical company focused on the development of specialized CAR-T cell-based therapies, on an exclusive agreement with Horizon Discovery Group plc (LSE: HZD), for the use of Horizon Discovery’s shRNA technology to generate Celyad’s second non-gene-edited allogeneic platform. Follow this link to download Celyad’s press release from Celyad’s website (external link).

Decision in AXA domain name dispute

On 20 August 2018, Bart GODDYN handed down a decision that ordered the transfer of the domain name “axaxlgroup.eu” to the legitimate owner of the well-known trademark “AXA”. AXA SA, is the holding company of the AXA Group which was founded in 1817 through the merger of several insurance companies. The AXA Group is known as a world leader in three major lines of business: property and casualty insurance, life…

Read More

Decision in Liu.Jo domain name dispute

On 11 October 2017, Bart GODDYN handed down a decision that ordered the transfer of the domain name “liujouomo.eu” to the legitimate owner of the well-known trademark “Liu.Jo”. Liu.Jo is an Italian company active in the business of manufacturing, marketing and selling high-end articles of clothing and accessories for women and men. Liu.Jo’s products can be found at flagship stores and retail stores (more than 5,300 worldwide). In the “liujouomo.eu”…

Read More

GODDYN supports Celyad

GODDYN starts a collaboration with Celyad for supporting the development of Celyad’s legal strategy and for the provision of legal services. Celyad SA (Euronext Brussels and Paris, and NASDAQ: CYAD) is a biopharmaceutical company, specialized in cell therapy, that is developing landmark technologies aimed at treating severe diseases with poor prognosis. Celyad’s scientific approach is inspired by the natural mechanisms that are used by the body to fight disease. Celyad…

Read More

Bart GODDYN speaker at IP World Summit 2017

Bart GODDYN served as speaker for the IP World Summit 2017 conference on 25-27 September 2017 in Amsterdam, The Netherlands. The IP World Summit, formerly known as Global Patent Congress, is a one-stop shop for IP leaders offering a mix of thought provoking and practical sessions now covering a range of approaches to IP protection and monetisation, including patents, trade secrets, designs, copyright, licensing and trademarks. The IP World Summit…

Read More

Legal IQ interview about trade secrets

Bart GODDYN was interviewed by Legal IQ (a division of IQPC) about trade secrets and the new European Trade Secrets Directive. Below is the transcript of the interview. Bart will be speaking about this topic at the IP World Summit in Amsterdam on the 25-27 of September 2017. Check out the agenda for more information: https://ipworldsummit.iqpc.com.   Firstly, could you summarise what a trade secret is and why someone would choose…

Read More

Bart GODDYN speaker at IICJ Conference 2017

Bart GODDYN served as panel moderator and speaker for the fifth International In-House Counsel Journal (IICJ) Conference on 28 March 2017 at the Law Society in London, UK. Senior in-house counsel drawn from all business sectors across Europe and North America attended the conference. The conference provided delegates with an ideal opportunity to discover the strategies and solutions companies are adopting across the full range in-house counsel management issues. Bart…

Read More

GODDYN joined FlandersBio

We have great pleasure in announcing that GODDYN has become part of FlandersBio’s membership list. FlandersBio is the networking organization for the life sciences sector in Flanders, a dynamic non-profit, fee-based organization with currently more than 340 members.

GODDYN assists TiGenix in deal with Takeda

GODDYN assists TiGenix in a licensing transaction with Takeda for TiGenix’s product Cx601. TiGenix NV (Euronext Brussels: TIG) and Takeda Pharmaceutical Company Limited (TSE: 4502) have entered into an exclusive ex-U.S. license, development and commercialization agreement for TiGenix’s product Cx601, a suspension of allogeneic adipose-derived stem cells (eASC) injected intra-lesionally for the treatment of complex perianal fistulas in patients with Crohn’s disease. TiGenix will receive an upfront cash payment of…

Read More

GODDYN advises TiGenix on Sepcell project

GODDYN advises TiGenix on TiGenix’s role as coordinator of the SEPCELL project. TiGenix (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms. TiGenix announced on 2 November 2015 that the SEPCELL project has been awarded a €5.4M grant from the European Commission under Horizon 2020, the European Union’s framework programme for research and innovation, to conduct a clinical Phase Ib/IIa trial…

Read More